Heart failure with preserved ejection fraction based on aging and comorbidities

Journal of Translational Medicine

Yali Zhao¹  Yao Yao²  Ying Lin³  Shihui Fu⁴  Yulong Li⁵  Leiming Luo⁵ 

[1] Central Laboratory, Hainan Hospital of Chinese People’s Liberation Army General Hospital, 572013, Sanya, China;Centre for the Study of Ageing and Human Development and Geriatrics Division, Medical School of Duke University, 27708, Durham, NC, USA;Centre for Healthy Ageing and Development Studies, National School of Development, Peking University, 100871, Beijing, China;Department of Cardiology, Hainan Hospital of Chinese People’s Liberation Army General Hospital, 572013, Sanya, China;Department of Cardiology, Hainan Hospital of Chinese People’s Liberation Army General Hospital, 572013, Sanya, China;Department of Geriatric Cardiology, Chinese People’s Liberation Army General Hospital, 100853, Beijing, China;Department of Geriatric Cardiology, Chinese People’s Liberation Army General Hospital, 100853, Beijing, China;

关键词: Aging;    Comorbidities;    Diagnosis;    Heart failure with preserved ejection fraction;    Treatment;   

DOI  :  10.1186/s12967-021-02935-x

来源: Springer

【 摘 要 】

Heart failure (HF) with preserved ejection fraction (HFpEF) is a leading cause of hospitalizations and mortality when diagnosed at the age of ≥ 65 years. HFpEF represents multifactorial and multisystemic syndrome and has different pathophysiology and phenotypes. Its diagnosis is difficult to be established based on left ventricular ejection fraction and may benefit from individually tailored approaches, underlying age-related changes and frequent comorbidities. Compared with the rapid development in the treatment of heart failure with reduced ejection fraction, HFpEF presents a great challenge and needs to be addressed considering the failure of HF drugs to improve its outcomes. Further extensive studies on the relationships between HFpEF, aging, and comorbidities in carefully phenotyped HFpEF subgroups may help understand the biology, diagnosis, and treatment of HFpEF. The current review summarized the diagnostic and therapeutic development of HFpEF based on the complex relationships between aging, comorbidities, and HFpEF.

【 授权许可】

CC BY